Now Playing
Island's $6.4B, Precision Neuro's $250M & the AI Control-Point Bet
Audio is available on Spreaker — see link below.
Enterprise browser Island reprices to $6.4B as capital rotates toward AI control points — plus Precision Neuroscience's $250M neural implant round, Pilgrim's biosurveillance seed, and two Chinese semiconductor raises. Six stories that map where institutional money is moving today.
Audio is available on Spreaker — see link below.
Island just raised four hundred million dollars at a six point four billion dollar valuation, and the timing tells you something important. This is a company that closed a two hundred and fifty million dollar round at four point eight billion just months ago.
The broader pattern across this funding cycle is worth holding onto. Capital is moving away from AI applications and toward control points.
Pilgrim closed a twenty-five million dollar seed round for ARGUS, an environmental threat detection system combining air sampling with genomic sequencing. Buckley Ventures led, with backing from people connected to Anthropic's red-team work.
Precision Neuroscience closed two hundred and fifty million dollars backed by Pershing Square and ARK Invest. The company makes minimally invasive neural implants and is moving from research settings toward clinical deployment.
Helsinki-based Kasvu raised thirty million euros for a Series A targeting neuroplasticity without the psychedelic experience. Their compound, KTX-0141, targets TrkB receptors to activate BDNF signaling, the mechanism believed to underpin antidepressant effects from psychedelics, while separating out the hallucinogenic component.
Two Chinese semiconductor raises round out the picture. Langxi Technology brought in the equivalent of roughly two hundred million yuan for embedded silicon capacitors and passive components used in GPU and CPU packaging.
Chapter summary auto-generated from the verified script. Listen to the full episode for the complete content.